Trial reportScience (New York, N.Y.)2025
Controlled colonization of the human gut with a genetically engineered microbial therapeutic.
Trial report in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The gut-kidney microbiome-oxalate axis in calcium oxalate nephrolithiasis: mechanisms and microbiome-based interventions.Frontiers in cellular and infection microbiology · 2026Pooled it
- Genome-integrated engineering ofSynthetic and systems biotechnology · 2027Article
- Microbiome-based therapeutics forGut microbes · 2026Review
- A Postbiotic-Inducing Ganoderma applanatum Polysaccharide Repairs the Intestinal Barrier via a Phocaeicola vulgatus - Tridecylic Acid Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- Firewalled synthetic commensal blocks horizontal gene transfer in the gut.bioRxiv : the preprint server for biology · 2026Article
- Systems engineering of engineered live biotherapeutics: A discovery-to-translation framework for streamlining microbiome therapeutic development.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Dopamine polymerization-mediated surface functionalization of living cells for advanced therapeutic applications.Nature protocols · 2026Review
- Article
- Harnessing pathogen stress-hormone sensing for living medicines.PLoS biology · 2026Article
- Metabolic engineering ofbioRxiv : the preprint server for biology · 2026Article
- Engineering commensal microbes for host health.Cell host & microbe · 2026Review
- Harnessing gut microbiome enzymes:Microbiology spectrum · 2026Article
- Orally available designed miniproteins inhibit enterotoxigenicbioRxiv : the preprint server for biology · 2026Article
- Advances in biocontainment strategies of engineered microbes for use in humans.Current opinion in microbiology · 2026Review
- Engineering probiotics as living biotherapeutics: a novel paradigm of restoring physiological barriers via targeted short-chain fatty acid delivery.Science China. Life sciences · 2026Article
- mGem: Applying microbiome therapeutic learnings to next-generation agricultural bioproducts.mBio · 2026Review
- Culturing microbiome therapeutics with big data.Nature biotechnology · 2026Article
- Gut microbiota: a potential therapeutic target for hyperuricemia and gout.Bioscience of microbiota, food and health · 2026Review
- Community Dynamics in a Changing World: highlights from the 1st Puerto Rico & Caribbean Microbiome Symposium and vision for a new microbiome hub.Sustainable microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Precision microbiome programming for therapeutic applications is limited by challenges in achieving reproducible colonic colonization. Previously, we created an exclusive niche that we used to engraft engineered bacteria into diverse microbiota in mice by using a porphyran prebiotic. Building on this approach, we have now engineered conditional attenuation into a porphyran-utilizing strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.